AG 555

133550-34-2

322.36

DMSO : >= 100 mg/mL (310.21 mM)

JAK/STAT Signaling; Protein Tyrosine Kinase/RTK; Anti-infection

AG 555 (Tyrphostin AG 555), a potent antiretroviral drug, is a potent and selective inhibitor of EGFR and blocks Cdk2 activation^[1][2]. IC50 & Target: EGFR^[1] In Vitro: AG 555 (100 uM) inhibits both the early stages (integration process) and the late stages (viral protein synthesis) in the virus life cycle^[1].
Tyrphostins AG555, which blocks Cdk2 activation, induces growth arrest of immortalized cells at G1-S and early S and is very effective in arresting the growth of EGFR overexpressor cells^[2].
Tyrphostin AG 555 can selectively suppress BPV-1 transcription through MAP kinase pathway activation and binding of phosphorylated Jun/ATF-2 at a novel intragenic regulatory sequence^[3].